Scholarship 24/08838-8 - Diabetes mellitus, Liberação controlada de fármacos - BV FAPESP
Advanced search
Start date
Betweenand

Synthesis of chitosan nanoparticles for encapsulation of antidiabetic drugs

Grant number: 24/08838-8
Support Opportunities:Scholarships in Brazil - Scientific Initiation
Start date until: August 01, 2024
End date until: July 31, 2025
Field of knowledge:Engineering - Materials and Metallurgical Engineering - Nonmetallic Materials
Principal Investigator:Dayane Batista Tada
Grantee:Giovana dos Santos Barreto
Host Institution: Instituto de Ciência e Tecnologia (ICT). Universidade Federal de São Paulo (UNIFESP). Campus São José dos Campos. São José dos Campos , SP, Brazil
Associated research grant:14/50907-5 - INCT 2014 - of obesity and diabetes, AP.TEM

Abstract

Diabetes Mellitus (DM) is a metabolic dysfunction related to cell glucose intake, categorized in two types: Type 2 DM, where the body develops insulin resistance, and Type 1 DM, an autoimmune disease where the body ceases to produce insulin, treated with multiple daily insulin injections. Type 2 DM can be treated and controlled, with significant reduction in symptoms and possible remission, when treated with medication, following medical instruction as well as implementing lifestyle changes for patients. Antidiabetic drugs have various mechanisms of action, and new drug pathways are in constant development. To help with blood sugar level regulation, Sotaglioflozin acts as a double inhibitor of sodium glucose cotransporters (SGLT) 1 and 2 that can be found in different tissues, but most commonly found in the intestines and kidneys. SGLT's regulation inhibits kidney glucose reabsorption, which helps lower blood sugar levels especially for Type 2 diabetics. However, drug testing revealed various side effects related to Sotaglioflozin use. Due to the positive effects of the medication for health and symptom reduction for type 2 diabetics, this project aims to synthesize polymeric Chitosan nanoparticles with encapsulated medication for controlled release and specific drug delivery to the kidneys. With targeted renal action, symptoms reduction as well as increased double SGLT inhibition effectiveness are expected.

News published in Agência FAPESP Newsletter about the scholarship:
More itemsLess items
Articles published in other media outlets ( ):
More itemsLess items
VEICULO: TITULO (DATA)
VEICULO: TITULO (DATA)

Please report errors in scientific publications list using this form.